Autres langues Northwest Biotherapeutics, Inc. Börse Stuttgart

Actions

NBYB

US66737P6007

Recherche biotechnologique et médicale

Temps Différé Börse Stuttgart Autres places de cotation 14:18:18 14/07/2026			Varia. 5j.	Varia. 1 janv.
0,1610 ^EUR	+0,62%		+0,62%	-21,84%

08/07	Northwest Biotherapeutics présente des données de survie actualisées de l'essai de phase III du DCVax-L contre le glioblastome	CI
15/05	Northwest Biotherapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Autres langues

08/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma
08/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
02/07	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
15/05	Northwest Biotherapeutics: Q1 Earnings Snapshot
15/05	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
30/04	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
21/04	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
21/04	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic
15/04	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
15/04	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt
20/11	Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
14/11	Northwest Biotherapeutics: Q3 Earnings Snapshot
14/11	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
14/11	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP
31/10/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC
27/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding
24/10/25	Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
24/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.
27/08/25	Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
27/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.
18/08/25	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
18/08/25	Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
15/08/25	Northwest Biotherapeutics: Q2 Earnings Snapshot
14/08/25	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
30/06/25	Northwest Biotherapeutics, Inc. announced that it expects to receive $2.85 million in funding from Yorkville Advisors Global LP